Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity
Authors:
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (19) , 5711-5714
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 ReceptorJournal of Medicinal Chemistry, 2010
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesityJournal of Clinical Investigation, 2010
- Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motifBioorganic & Medicinal Chemistry Letters, 2010
- Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood–brain-barrierBioorganic & Medicinal Chemistry Letters, 2010
- Excellent correlation between substituent constants and pyridinium N-methyl chemical shiftsTetrahedron Letters, 2009
- Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in miceBioorganic & Medicinal Chemistry Letters, 2009
- CB1 receptor antagonism: biological basis for metabolic effectsDrug Discovery Today, 2008
- Conformationally Constrained Analogues of N-(Piperidinyl)-5-(4-Chlorophenyl)-1-(2,4- Dichlorophenyl)-4-Methyl-1H-Pyrazole-3-Carboxamide (SR141716): Design, Synthesis, Computational Analysis, And Biological EvaluationsJournal of Medicinal Chemistry, 2008
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrierInternational Journal of Pharmaceutics, 2005